Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers

This book delves into the various aspects of the renin-angiotensin-aldosterone system (RAAS) and its role in cardiovascular disorders. It explores the use of anti-hypertensive agents, with a focus on (ACE) angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs). The chapters cover topics such as the preferred use of ACE inhibitors over ARBs in high-risk patients, the impact of these agents on insulin resistance, their role in acute heart failure and peripheral artery disease, and their immunomodulatory activity in hypertensive patients. Additionally, the book examines the role of ACE inhibitors and ARBs in COVID-19 patients and provides insights into recent trends in managing hypertension through RAAS inhibition.

It serves as a valuable resource for researchers, clinicians, and healthcare professionals involved in the field of cardiovascular medicine.

A Machine-Generated Literature Overview of ACE Inhibitors vs. Angiotensin Receptor Blockers (ARBs) Delves in the analysis of the superiority of ACE inhibitors over ARBs as RAAS inhibitors in high-risk patients Explains the effects of ACE inhibitors and ARBs, including their impact on insulin resistance & immunomodulation

Autorentext

Dr. Mukesh Nandave is an In-charge Director of the School of Pharmaceutical Sciences, Associate Dean (Research), and head of the Department of Pharmacology and Pharmaceutical Biotechnology at Delhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, New Delhi, India. He has earlier served as associate professor and head of the Department of Pharmacology at NMIMS University, Mumbai (2010-2017). He has also worked as a research scientist in the Medical Affairs and Clinical Research Department of Ranbaxy Research Laboratories (currently known as Sun Pharmaceutical Industries Limited, Gurugram). Dr. Nandave earned his Ph. D. in pharmacology from AIIMS, Delhi and received his post-doctoral training from the Division of Cardiothoracic Surgery, the Ohio State University Medical Center, Columbus, USA.

For more than 20 years, Dr. Nandave has investigated the role of nutraceuticals, herbomineral formulations, and phytoconstituents for myocardial ischemia & reperfusion injury, diabetes, obesity, and pain management. His lab received more than 3.5 crore total funding from Govt. (DBT, DST, ICMR, and AYUSH) as well as industry (Pharmazz, Dabur, Fertis India, Charak Pharma, Madhavbaug, and Sandu Pharma). He has published over 100 papers in peer-reviewed national and international journals, books, and book chapters.

Dr. Nandave has received numerous awards including the Distinguished Leadership Award of International Academy of Cardiovascular Sciences; Prof. S. C. Lahiri Oration and G. Achari Gold Medal by Indian Pharmacological Society; Association of Pharmaceutical Teachers of India (APTI) Young Pharmacy Teacher of the Year Award, Early Investigator Award by International Society for Heart Research, Prof. Duggirala Visweswaram & Prof. Sreemantula Satyanarayana Prize; Best Research Output of the Year for 2014-2015, 2013-2014, and 2012-2013 Award" of SVKM's NMIMS University.

Dr. Nandave is secretary general, of the International Academy of Cardiovascular Sciences (IACS)-India section and treasurer of the Society for Promotion and Research of Cardiovascular Sciences (SPARCS). He is a life member of various professional bodies including the International Society for Heart Research (ISHR), the International Academy of Cardiovascular Sciences (IACS); the Indian Pharmacological Society (IPS); the Indian Pharmaceutical Association (IPA); the Association of Physiologist and Pharmacologist of India (APPI); Association of Pharmaceutical Teachers of India (APTI); and Society for Ethnopharmacology.

Inhalt

Chapter 1 Introduction of the renin-angiotensin-aldosterone system (RAAS).- Chapter 2 Role of anti-hypertensive agents in cardiovascular disorders.- Chapter 3 (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs).- Chapter 4 Role of (ACE) angiotensin-converting enzyme inhibitors in transforming reninangiotensin system.- Chapter 5 The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients.- Chapter 6 Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure.- Chapter 7 Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients.- Chapter 8 Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease.- Chapter 9 Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients.- Chapter 10 Recent trends in the management of hypertension through RAAS inhibition.